Recently, I received a notice from the American Institute for medical and biological engineering. In view of Dr. Wang Peng's outstanding contributions in this field, I was accepted as an aim fellow and invited to attend the inauguration ceremony in Washington, USA on March 19-20, 2017.
About members of the American Academy of medicine and Bioengineering
AIMBE ( http://aimbe.org/ ）It is a well-known non-profit organization in the field of international medicine and bioengineering in Washington, D.C., and belongs to the American Academy of Sciences. The aim fellow is composed of the most outstanding (top 2%) in the field of medicine and bioengineering in the world. It must be recommended by the current fellow, screened in two rounds and voted by all the fellow members.
AIMBE College of fellows currently brings together 1500 experts from academia, industry, government, innovative and characteristic medical and bioengineering fields, and strives to improve social medical care and safety! Among the fellows, 7 won the presidential science and Technology Innovation Award, 132 were members of the American Academy of engineering, 41 were members of the American Academy of medicine and 94 were members of the American Academy of Sciences.
About Dr. Wang Peng
Dr. Wang Peng, a distinguished expert of the "thousand talents plan", is currently the vice president of Yabao pharmaceutical, the president of Beijing Pharmaceutical Research Institute of Yabao Pharmaceutical Group and the president of Suzhou Yabao pharmaceutical R & D Co., Ltd.
He has been engaged in the research and development of innovative drugs at Schering plough Research Institute for 18 years, and has made significant contributions to the discovery and early development of 9 candidate drugs; In 2008, he was hired by Shanghai pharming Kant and returned to China as its vice president and head of R & D biology; In 2009, Wang Peng was invited to join Xiansheng Pharmaceutical Group as vice president and scientific officer; In 2013, he officially joined Yabao pharmaceutical and served as the president of Beijing Pharmaceutical Research Institute. In 2014, he established Suzhou Yabao pharmaceutical research and Development Co., Ltd., a biological company committed to developing revolutionary and innovative drugs with international prospects through international cooperation.
Innovation, openness and cooperation
www.suzhouyabao.com
December 2016
请将简历发送至：